Condition: Multiple Myeloma (MM) · Non-Hodgkin Lymphoma (NHL) · Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of OriV508 injection for patients with relapsed/refractory hematological malignancies.
This description comes directly from the study's public registry record.
Heng Mei, Ph.D&M.D · 027-8572600 · hmei@hust.edu.cn
Jia Xu, Ph.D · +86 18274201261 · xu_jia@hust.edu.cn
Always discuss trial participation with your own doctor first.
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07101705